Skip to Content
Merck
  • Knock-in model of Dravet syndrome reveals a constitutive and conditional reduction in sodium current.

Knock-in model of Dravet syndrome reveals a constitutive and conditional reduction in sodium current.

Journal of neurophysiology (2014-05-09)
Ryan J Schutte, Soleil S Schutte, Jacqueline Algara, Eden V Barragan, Jeff Gilligan, Cynthia Staber, Yiannis A Savva, Martin A Smith, Robert Reenan, Diane K O'Dowd
ABSTRACT

Hundreds of mutations in the SCN1A sodium channel gene confer a wide spectrum of epileptic disorders, requiring efficient model systems to study cellular mechanisms and identify potential therapeutic targets. We recently demonstrated that Drosophila knock-in flies carrying the K1270T SCN1A mutation known to cause a form of genetic epilepsy with febrile seizures plus (GEFS+) exhibit a heat-induced increase in sodium current activity and seizure phenotype. To determine whether different SCN1A mutations cause distinct phenotypes in Drosophila as they do in humans, this study focuses on a knock-in line carrying a mutation that causes a more severe seizure disorder termed Dravet syndrome (DS). Introduction of the DS SCN1A mutation (S1231R) into the Drosophila sodium channel gene para results in flies that exhibit spontaneous and heat-induced seizures with distinct characteristics and lower onset temperature than the GEFS+ flies. Electrophysiological studies of GABAergic interneurons in the brains of adult DS flies reveal, for the first time in an in vivo model system, that a missense DS mutation causes a constitutive and conditional reduction in sodium current activity and repetitive firing. In addition, feeding with the serotonin precursor 5-HTP suppresses heat-induced seizures in DS but not GEFS+ flies. The distinct alterations of sodium currents in DS and GEFS+ GABAergic interneurons demonstrate that both loss- and gain-of-function alterations in sodium currents are capable of causing reduced repetitive firing and seizure phenotypes. The mutation-specific effects of 5-HTP on heat-induced seizures suggest the serotonin pathway as a potential therapeutic target for DS.

MATERIALS
Product Number
Brand
Product Description

Supelco
Cimetidine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
3-Iodo-L-tyrosine
Sigma-Aldrich
Histamine, ≥97.0%
Sigma-Aldrich
Cimetidine
Supelco
Levodopa, Pharmaceutical Secondary Standard; Certified Reference Material
Cimetidine, European Pharmacopoeia (EP) Reference Standard
Levodopa, European Pharmacopoeia (EP) Reference Standard
Supelco
Histamine, analytical standard
USP
Levodopa, United States Pharmacopeia (USP) Reference Standard
USP
Cimetidine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
3,4-Dihydroxy-L-phenylalanine, ≥98% (TLC)
Cimetidine for peak identification, European Pharmacopoeia (EP) Reference Standard
Cimetidine for system suitability, European Pharmacopoeia (EP) Reference Standard